Generation of hen egg lysozyme-specific and major histocompatibility complex class I-restricted cytolytic T lymphocytes: recognition of cytosolic and secreted antigen expressed by transfected cells. 1990

F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
Immunobiologie Moléculaire, CNRS-ENS UMR 49, Lyon, France.

Syngeneic cells exogenously supplied with hen egg lysozyme (HEL) or endogenously synthesizing HEL were used as antigen-presenting cells to induce major histocompatibility complex class I-restricted cytotoxic T lymphocytes (CTL). Immunization of C57BL/6 mice followed by repeated stimulation of their splenocytes in vitro with trypsinized HEL peptides led to the generation of CTL lines specific for trypsinized HEL peptides and restricted by H-2K. Immunization of C3H mice with a mixture of soluble native HEL and irradiated syngeneic spleen cells followed by in vitro stimulation of immune spleen cells with soluble HEL could in a few cases result in HEL-specific CTL able to kill syngeneic transfectant L cells secreting HEL (HELs) or expressing cytosol-targeted HEL (HELc). The use of HELs or HELc transfectant L cells as in vivo and in vitro immunogens was a potent way for eliciting HEL-specific polyclonal CTL. These CTL and two CD8+ clones were found to be H-2K restricted and specific for the 1-17 N-terminal HEL peptide. In addition, the anti-HEL CTL could also exhibit a significant cross-reactivity against unsensitized and HEL-untransfected targets expressing the K restriction element. This cross-reactivity was likely due to recognition of unidentified HEL mimicking peptides (self-derived?) presented by the MHC class I (H-2K or H-2K) molecule used as the restriction element for the specific recognition of HEL. The CTL raised after immunization with HELs or HELc transfectant cells were found to recognize both the HELs and HELc transfectant cells even though HEL was not detected in the latter after a 2- or 5-min radiolabeling pulse. Recognition of both HELs and HELc transfectant cells by a given CTL clone suggests that HEL subjected to two separate processing pathways, each depending on the initial subcellular localization, can ensure the generation of similar MHC class I peptide complexes.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009113 Muramidase A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17. Lysozyme,Leftose,N-Acetylmuramide Glycanhydrolase,Glycanhydrolase, N-Acetylmuramide,N Acetylmuramide Glycanhydrolase
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
October 1987, European journal of immunology,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
January 1994, The Journal of experimental medicine,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
August 1994, The Journal of experimental medicine,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
February 1993, Canadian journal of microbiology,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
September 1985, Proceedings of the National Academy of Sciences of the United States of America,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
July 1995, Annals of the New York Academy of Sciences,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
January 1989, Annual review of immunology,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
May 2004, Immunology,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
July 1986, European journal of immunology,
F Forquet, and V Calin, and M C Trescol-Biemont, and J Kanellopoulos, and E Mottez, and P Kourilsky, and C Rabourdin-Combe, and D Gerlier
December 1992, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!